Key result
Right atrial pressure-corrected cardiac power output (CPORAP) was independently associated with event-free survival (HR 0.211) and provided significantly better prognostic discrimination than uncorrected CPO.
Why the study?
The prognostic performance of right atrial pressure-corrected cardiac power output in heart failure with preserved ejection fraction remained unknown.
Does right atrial pressure-corrected cardiac power output (CPORAP) provide better prognostic performance than standard CPO in patients with HFpEF and pulmonary hypertension?
Cohort (n=101)
No
Does right atrial pressure-corrected cardiac power output (CPORAP) provide better prognostic performance than standard CPO in patients with HFpEF and pulmonary hypertension?
Hazard Ratio: 0.211 (95% CI 0.052–0.864)
In patients with HFpEF and pulmonary hypertension, right atrial pressure-corrected cardiac power output (CPORAP) provides superior prognostic discrimination for adverse events compared to standard cardiac power output.
Cardiac power output (CPO) is a powerful predictor of adverse outcomes in heart failure (HF). However, the original formula of CPO included the difference between mean arterial pressure and right atrial pressure (RAP). The prognostic performance of RAP-corrected CPO (CPO RAP ) remains unknown in heart failure with preserved ejection fraction (HFpEF). We studied 101 HF patients with a left ventricular ejection fraction > 40% who had pulmonary hypertension due to left heart disease. CPO RAP was significantly more discriminating than CPO in predicting outcomes (Delong test, P = 0.004). Twenty-five (24.8%) patients presented with dis-concordantly high CPO RAP and low CPO when stratified by the identified CPO RAP threshold of 0.547 W and the accepted CPO threshold of 0.803 W. These patients had the lowest RAP, and their cumulative incidence was comparable with those with concordantly high CPO and CPO RAP ( P = 0.313). CPO RAP might identify patients with right ventricular involvement, thereby providing better prognostic performance than CPO in HFpEF.
No takes yet. Share an insight, caveat, or question.
Wu et al. (2023) conducted a cohort in Heart failure with preserved ejection fraction and pulmonary hypertension (n=101). Right atrial pressure-corrected cardiac power output (CPORAP) vs. Cardiac power output (CPO) was evaluated on Event-free survival (HR 0.211, 95% CI 0.052-0.864). Right atrial pressure-corrected cardiac power output (CPORAP) was independently associated with event-free survival (HR 0.211) and provided significantly better prognostic discrimination than uncorrected CPO.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: